Miglustat — Membership Pricing

Other medications in Metabolic

• Nitisinone
• Patisiran
• Sapropterin
• Tafamidis
• Vestronidase Alfa
• Asfotase Alfa
• Cerliponase Alfa
• Eliglustat

About Miglustat

Miglustat is a specialized medication used for rare genetic conditions, often associated with significant costs. At TheDrugClub, we understand the challenges of affording essential prescriptions. Our membership program is designed to help you access potential savings on medications like miglustat, making vital treatments more manageable for you and your family.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Miglustat is approved for (FDA label)

Miglustat is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option.( 1.1 ) 1.1 Type 1 Gaucher Disease Miglustat is indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access).

Source: Read the full FDA label on DailyMed. Label effective date: December 31, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Miglustat (FDA label)

Capsules: 100 mg of miglustat, hard gelatin capsules with white opaque cap imprinted "NAV" with black ink and white opaque body imprinted "104" with black ink. Capsules : 100 mg

Source: FDA prescribing information (DailyMed). Set ID: aa9a3ab6-2376-4b52-9e54-15dc87f25260. SPL document ID: 94491d95-3cdd-45cd-b94c-a0d4982618cc. Label effective date: December 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Miglustat (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: Peripheral Neuropathy [see Warnings and Precautions ( 5.1 )] Tremor [see Warnings and Precautions ( 5.2 )] Diarrhea and Weight Loss [see Warnings and Precautions ( 5.3 )] Reductions in Platelet Count [see Warnings and Precautions ( 5.4 )] The most common adverse reactions (incidence ≥5%) are: diarrhea, weight loss, stomach pain, gas, nausea and vomiting headache including migraine, tremor, leg cramps, dizziness, weakness, vision problems, thrombocytopenia, muscle cramps, back pain, constipation, dry mouth, heaviness in arms and legs, memory loss, unsteady walking, anorexia, indigestion, paresthesia, stomach bloating, stomach pain not related to food, and menstrual changes ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: aa9a3ab6-2376-4b52-9e54-15dc87f25260. SPL document ID: 94491d95-3cdd-45cd-b94c-a0d4982618cc. Label effective date: December 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Miglustat (FDA label)

None. None ( 4 ).

Source: FDA prescribing information (DailyMed). Set ID: aa9a3ab6-2376-4b52-9e54-15dc87f25260. SPL document ID: 94491d95-3cdd-45cd-b94c-a0d4982618cc. Label effective date: December 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Miglustat (FDA label)

Peripheral neuropathy : Perform baseline and follow-up neurological evaluations at 6-month intervals in all patients ( 5.1 ). Tremor : Reduce dose to ameliorate tremor or discontinue treatment if tremor does not resolve within days of dose reduction ( 5.2 ). Diarrhea and weight loss : Evaluate for underlying gastrointestinal disease in patients who do not respond to usual interventions (e.g. diet modification) ( 5.3 ). Reductions in Platelet Count : Mild reductions in platelet counts without association with bleeding were observed in some patients. Monitoring of platelet counts is recommended ( 5.4 ). 5.1 Peripheral Neuropathy In clinical trials, cases of peripheral neuropathy have been reported in 3% of Gaucher's patients treated with miglustat. All patients receiving miglustat treatment should undergo baseline and repeat neurological evaluations at approximately 6-month intervals.

Source: FDA prescribing information (DailyMed). Set ID: aa9a3ab6-2376-4b52-9e54-15dc87f25260. SPL document ID: 94491d95-3cdd-45cd-b94c-a0d4982618cc. Label effective date: December 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Miglustat (FDA label)

While co-administration of miglustat appeared to increase the clearance of imiglucerase by 70%, these results are not conclusive because of the small number of patients studied and because patients took variable doses of imiglucerase [see Clinical Pharmacology ( 12.3 )]. Co-administration of miglustat and imiglucerase may lead to increased clearance of imiglucerase.

Source: FDA prescribing information (DailyMed). Set ID: aa9a3ab6-2376-4b52-9e54-15dc87f25260. SPL document ID: 94491d95-3cdd-45cd-b94c-a0d4982618cc. Label effective date: December 31, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.